Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 4/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | GPX4 | P36969 | 5/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460052 | 0.76 | SLC6A9 (0.48) | SLC6A9OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5456087 | 0.76 | SLC6A9 (0.45) | SLC6A9OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5454642 | 0.76 | SLC6A9 (0.45) | SLC6A9OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5456083 | 0.76 | SLC6A9 (0.45) | SLC6A9OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4922750 | 0.73 | SLC6A9 (0.42) | SLC6A9OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL30301668 | 0.72 | SLC6A9 (0.44) | SLC6A9OPRM1OPRD1OPRL1 | |
| SCHEMBL5450720 | 0.70 | SLC6A9 (0.46) | SLC6A9OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5461121 | 0.70 | SLC6A9 (0.44) | SLC6A9 | |
| SCHEMBL5454596 | 0.70 | SLC6A9 (0.44) | SLC6A9 | |
| SCHEMBL5450711 | 0.70 | SLC6A9 (0.46) | SLC6A9OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066587-A1 | Substituted azetidine compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-03-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066587-A1 | Substituted azetidine compounds, their preparation and use as medicaments | AZI2, NISCH, QDPR | SLC6A9 1388/4885OPRM1 829/4885OPRD1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.